Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edoxaban vs Warfarin After Heart Valve Repair or Bioprosthetic Replacement (ENAVLE)
NCT03244319Phase 3Completed
- Sponsor
- Yonsei University
- Start
- Dec 2017
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of edoxaban in thromboembolism (2 arms), sponsored by Yonsei University. Primary endpoint: Occurrence of thromboembolic event at 12 weeks. Started Dec 2017; status: completed.
02
Drugs
edoxaban
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT03244319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03244319.